The Fully Absorbable Scaffold Feasibility Study (FAST) is a prospective, single arm study designed to assess the safety and performance of this next generation scaffold for the treatment of atherosclerotic coronary lesions.
The first patients in the study were enrolled by Professor Ian Meredith, primary investigator and director of MonashHeart, at Monash Medical Centre in Melbourne, Australia. The study will enroll up to 30 patients.
"By virtue of its unique design properties, incorporating thinner struts and enabling greater stent expansion while maintaining radial strength, this fully resorbable scaffold technology may potentially overcome a number of limitations with first generation absorbable scaffolds," said Professor Meredith.
The resorbable polymer scaffold incorporates several key design elements from the Boston Scientific SYNERGY Stent System, including a resorbable polymer and an ultrathin everolimus coating which is applied abluminally (on the exterior) to the scaffold.
It also features a delivery system built with Boston Scientific expertise designed to facilitate improved acute performance.
"We are taking the best of our SYNERGY stent and applying it to our new, fully resorbable scaffold technology," said Kevin Ballinger, president, Interventional Cardiology, Boston Scientific. "We continue to invest in meaningful innovations designed to provide better outcomes for patients with coronary artery disease."
The Boston Scientific fully resorbable scaffold technology is under development and is not available for sale. The SYNERGY Stent is an investigational device in the US and Japan, and is not available for sale in those countries.
The SYNERGY Stent has CE mark approval and is available for sale in countries where CE mark is accepted.
